Trial reportThe American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry2009
Citalopram for continuation therapy after repetitive transcranial magnetic stimulation in vascular depression.
Trial report in The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Citalopram versus other anti-depressive agents for depression.The Cochrane database of systematic reviews · 2012Pooled it
- The effect of fluoxetine combined with repetitive transcranial magnetic stimulation on the psychological emotions and cognitive and neurological functions of acute post-stroke depression patients.American journal of translational research · 2021Article
- Evaluation and Treatment of Vascular Cognitive Impairment by Transcranial Magnetic Stimulation.Neural plasticity · 2020Review
- Late-life depression: evidence-based treatment and promising new directions for research and clinical practice.The Psychiatric clinics of North America · 2011Review
- Brain stimulation in psychiatry and its effects on cognition.Nature reviews. Neurology · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
objectivesThe authors previously reported that repetitive transcranial magnetic stimulation (rTMS) produced a response rate of 39.4% among 62 patients with treatment resistant vascular depression. This study was undertaken to assess the outcome of continuation therapy to prevent relapse among these patients during 9 weeks after completion of rTMS.
designPatients were randomly assigned to 18,000 pulses of rTMS given over 3 weeks or sham treatment using double blind methods. After rTMS, all patients were given 20 mg/day of citalopram for 9 weeks and reevaluated at 3, 6, and 9 weeks.
settingOutpatient continuation treatment trial.
participantsPatients with vascular depression (N = 62), as determined by magnetic resonance imaging hyperintensities and three or more clinical risk factors for vascular disease without other major medical illness, were recruited. They had onset of major depression after age 50 and failed at least one trial of antidepressants.
interventionAfter rTMS or sham treatment, all treatment responders were given citalopram for 9 weeks.
resultsAmong the 33 patients who were given rTMS, 13 responded (i.e., >50% decline in Hamilton Depression Scale score). Of these 13, all completed the 9 weeks of continuation treatment. There were nine patients who continued to be responders and four who had a relapse of depression.
conclusionMore effective methods are needed to treat elderly patients with treatment resistant vascular depression and to prevent relapse among treatment responders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.